{"id":7491,"date":"2026-05-29T11:00:00","date_gmt":"2026-05-29T11:00:00","guid":{"rendered":"https:\/\/regenerated.com\/blog\/oxygen-therapy-for-copd\/"},"modified":"2026-08-23T09:52:07","modified_gmt":"2026-08-23T09:52:07","slug":"oxygen-therapy-for-copd","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/oxygen-therapy-for-copd\/","title":{"rendered":"Oxygen Therapy for COPD: When It Helps, When It Doesn&#8217;t, and How It Works"},"content":{"rendered":"<p><strong>Long-term oxygen therapy is the single treatment proven to extend life in COPD patients with severe hypoxemia. Two landmark trials from the early 1980s showed that supplemental oxygen for at least 15 hours a day reduces mortality in patients with dangerously low blood oxygen. Those findings still anchor every major guideline, including the 2024 GOLD report. Oxygen does not help COPD patients with only moderate desaturation.<\/strong><\/p>\n<div class=\"bb-evidence-meter\">\n<div class=\"bb-evidence-meter__title\">Evidence Strength: Oxygen Therapy in COPD<\/div>\n<div class=\"bb-evidence-meter__item\">\n<span class=\"bb-evidence-meter__label\">LTOT for severe resting hypoxemia (survival)<\/span><\/p>\n<div class=\"bb-evidence-meter__bar\">\n<div class=\"bb-evidence-meter__fill bb-evidence-meter__fill--strong\" style=\"width:90%\">Strong<\/div>\n<\/div>\n<\/div>\n<div class=\"bb-evidence-meter__item\">\n<span class=\"bb-evidence-meter__label\">88 to 92% titration target (harm from over-oxygenation)<\/span><\/p>\n<div class=\"bb-evidence-meter__bar\">\n<div class=\"bb-evidence-meter__fill bb-evidence-meter__fill--strong\" style=\"width:80%\">Strong<\/div>\n<\/div>\n<\/div>\n<div class=\"bb-evidence-meter__item\">\n<span class=\"bb-evidence-meter__label\">Oxygen for moderate desaturation (strong evidence of NO benefit)<\/span><\/p>\n<div class=\"bb-evidence-meter__bar\">\n<div class=\"bb-evidence-meter__fill bb-evidence-meter__fill--strong\" style=\"width:78%\">Strong (null)<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>Oxygen therapy is not appropriate for every person with COPD. The evidence is specific about who benefits and who does not, and getting it wrong can worsen outcomes. This guide walks through the qualifying criteria, the trials behind them, the correct flow rates and targets, and the situations where oxygen adds burden without benefit.<\/p>\n<div style=\"background:#f0f7fa;border-left:4px solid #0077b6;padding:20px 24px;margin:28px 0\">\n<h3 style=\"margin-top:0;color:#0077b6\">Key Takeaways<\/h3>\n<ul style=\"margin-bottom:0\">\n<li>Long-term oxygen therapy (LTOT) reduces mortality in COPD patients with severe resting hypoxemia (PaO2 at or below 55 mmHg or SpO2 at or below 88%).<\/li>\n<li>The NOTT trial (1980) and MRC trial (1981) established that more hours of daily oxygen use produce better survival.<\/li>\n<li>Oxygen does NOT benefit COPD patients with only moderate desaturation, as shown by the LOTT trial (2016).<\/li>\n<li>Target SpO2 in COPD is 88 to 92%, not the 94%+ used for most other conditions.<\/li>\n<li>Oxygen must be prescribed and titrated by a physician. Too much oxygen in COPD can suppress breathing drive and worsen hypercapnia.<\/li>\n<\/ul>\n<\/div>\n<h2>When Is Oxygen Therapy Prescribed for COPD?<\/h2>\n<p>Oxygen therapy is prescribed when COPD has progressed to the point where the lungs can no longer maintain adequate blood oxygen on their own. This chronic hypoxemia develops gradually as lung tissue is destroyed.<\/p>\n<p>The criteria are specific. According to the GOLD 2024 guidelines, long-term oxygen therapy is indicated when:<sup><a href=\"#ref-1\">1<\/a><\/sup><\/p>\n<ul>\n<li>Resting PaO2 (partial pressure of oxygen in arterial blood) is at or below 55 mmHg, OR<\/li>\n<li>Resting SpO2 (oxygen saturation) is at or below 88%, OR<\/li>\n<li>PaO2 is between 55 and 60 mmHg with evidence of pulmonary hypertension, peripheral edema suggesting heart failure, or polycythemia (hematocrit above 55%).<\/li>\n<\/ul>\n<p>These values must be confirmed on two separate occasions, at least three weeks apart, while the patient is clinically stable and on optimal medical therapy. A single low reading during an exacerbation does not qualify. Where low oxygen stems from pulmonary hypertension, our guide to <a href=\"https:\/\/regenerated.com\/blog\/pulmonary-hypertension-oxygen-therapy\/\">oxygen therapy for pulmonary hypertension<\/a> covers the overlap.<\/p>\n<div class=\"bb-stat-callout\"><span class=\"bb-stat-number\">22% vs 41%<\/span><span class=\"bb-stat-label\">24-month mortality on continuous oxygen versus nocturnal-only oxygen in severe COPD hypoxemia<\/span><span class=\"bb-stat-source\">NOTT Group, Annals of Internal Medicine, 1980<\/span><\/div>\n<h2>What Does the Evidence Say About Oxygen Therapy for COPD?<\/h2>\n<h3>The NOTT Trial (1980)<\/h3>\n<p>The Nocturnal Oxygen Therapy Trial randomized 203 patients with COPD and severe hypoxemia to either continuous oxygen (averaging 17.7 hours per day) or nocturnal-only oxygen (averaging 12 hours per day).<sup><a href=\"#ref-2\">2<\/a><\/sup><\/p>\n<p>After 24 months, mortality in the nocturnal-only group was nearly double that of the continuous group (41% versus 22%). The message was direct: more oxygen hours meant better survival.<\/p>\n<h3>The MRC Trial (1981)<\/h3>\n<p>The Medical Research Council trial, run across three UK centers, randomized 87 patients with severe COPD, hypoxemia, and cor pulmonale (right-sided heart failure from lung disease) to either oxygen therapy (at least 15 hours daily, including overnight) or no oxygen.<sup><a href=\"#ref-3\">3<\/a><\/sup><\/p>\n<p>Over five years, the oxygen group had significantly better survival, with mortality in the no-oxygen group roughly double that of the treated group. Combined with NOTT, this established LTOT as standard of care for severe COPD hypoxemia.<\/p>\n<h3>The LOTT Trial (2016)<\/h3>\n<p>For decades after NOTT and MRC, clinicians wondered whether oxygen might also help COPD patients with moderate desaturation (SpO2 89 to 93%). The Long-Term Oxygen Treatment Trial answered this.<sup><a href=\"#ref-4\">4<\/a><\/sup><\/p>\n<p>LOTT randomized 738 patients with stable COPD and moderate resting or exercise-induced desaturation to either supplemental oxygen or no supplemental oxygen. After a median 18.4 months of follow-up, there was no difference in time to death, first hospitalization, COPD exacerbations, quality of life, or exercise capacity.<\/p>\n<div class=\"bb-stat-callout\"><span class=\"bb-stat-number\">0<\/span><span class=\"bb-stat-label\">Measurable benefit from supplemental oxygen in COPD patients with only moderate desaturation, across death, hospitalization, and quality of life<\/span><span class=\"bb-stat-source\">LOTT Research Group, NEJM, 2016<\/span><\/div>\n<p>The conclusion: supplemental oxygen does not help patients whose oxygen levels are only moderately reduced. Prescribing it in this group adds cost, inconvenience, and equipment burden with no measurable payoff.<\/p>\n<table style=\"width:100%;border-collapse:collapse;margin:28px 0\">\n<thead>\n<tr style=\"background:#0077b6;color:white\">\n<th style=\"padding:12px;text-align:left\">Trial<\/th>\n<th style=\"padding:12px;text-align:left\">Year<\/th>\n<th style=\"padding:12px;text-align:left\">Patients<\/th>\n<th style=\"padding:12px;text-align:left\">Key Finding<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #ddd\">\n<td style=\"padding:12px\">NOTT<\/td>\n<td style=\"padding:12px\">1980<\/td>\n<td style=\"padding:12px\">203 (severe hypoxemia)<\/td>\n<td style=\"padding:12px\">Continuous O2 nearly halved mortality vs nocturnal-only<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #ddd\">\n<td style=\"padding:12px\">MRC<\/td>\n<td style=\"padding:12px\">1981<\/td>\n<td style=\"padding:12px\">87 (severe hypoxemia + cor pulmonale)<\/td>\n<td style=\"padding:12px\">15+ hrs\/day O2 roughly halved 5-year mortality vs no O2<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:12px\">LOTT<\/td>\n<td style=\"padding:12px\">2016<\/td>\n<td style=\"padding:12px\">738 (moderate desaturation)<\/td>\n<td style=\"padding:12px\">No benefit from oxygen in moderate desaturation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>What Is the Right Oxygen Flow Rate for COPD?<\/h2>\n<p>COPD oxygen therapy uses lower flow rates and a lower saturation target than most other conditions. This reflects COPD physiology, not caution for its own sake. For a broader reference across conditions, see our <a href=\"https:\/\/regenerated.com\/blog\/oxygen-therapy-flow-rate-chart\/\">oxygen therapy flow rate chart<\/a>.<\/p>\n<h3>Why 88 to 92%, Not 94%+<\/h3>\n<div style=\"background:#f0f7fa;border-left:4px solid #0077b6;padding:16px 22px;margin:24px 0\">\n<p style=\"margin:0 0 10px\"><strong>Most conditions:<\/strong> clinicians target SpO2 above 94 to 95% to fully saturate the blood.<\/p>\n<p style=\"margin:0 0 10px\"><strong>COPD:<\/strong> the target is deliberately lower, 88 to 92%.<\/p>\n<p style=\"margin:0\"><strong>The reason:<\/strong> many COPD patients retain CO2 (hypercapnia). Pushing SpO2 above 92% can blunt respiratory drive and shift CO2 off hemoglobin (the Haldane effect), raising blood CO2 and risking respiratory acidosis. The lower target keeps oxygen adequate without triggering that cascade.<\/p>\n<\/div>\n<p>Austin and colleagues demonstrated the danger in a 2010 BMJ randomized trial. In a prehospital setting, COPD patients given high-flow oxygen targeting 100% saturation had significantly higher mortality than those given titrated oxygen targeting 88 to 92%.<sup><a href=\"#ref-5\">5<\/a><\/sup><\/p>\n<h3>Typical Flow Rates<\/h3>\n<p>Most COPD patients on LTOT use a low-flow nasal cannula at 1 to 3 liters per minute (L\/min), titrated individually to hold SpO2 within 88 to 92%. Some need different rates at rest versus during exertion or sleep.<\/p>\n<table style=\"width:100%;border-collapse:collapse;margin:28px 0\">\n<thead>\n<tr style=\"background:#0077b6;color:white\">\n<th style=\"padding:12px;text-align:left\">Activity<\/th>\n<th style=\"padding:12px;text-align:left\">Typical Flow Rate<\/th>\n<th style=\"padding:12px;text-align:left\">Target SpO2<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #ddd\">\n<td style=\"padding:12px\">Rest<\/td>\n<td style=\"padding:12px\">1-2 L\/min<\/td>\n<td style=\"padding:12px\">88-92%<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #ddd\">\n<td style=\"padding:12px\">Exercise\/Activity<\/td>\n<td style=\"padding:12px\">2-4 L\/min (titrated)<\/td>\n<td style=\"padding:12px\">88-92%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:12px\">Sleep<\/td>\n<td style=\"padding:12px\">1-2 L\/min (may increase by 1 L\/min)<\/td>\n<td style=\"padding:12px\">88-92%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>What Types of Oxygen Therapy Are Used in COPD?<\/h2>\n<h3>Long-Term Oxygen Therapy (LTOT)<\/h3>\n<p>LTOT means using supplemental oxygen for at least 15 hours per day, including during sleep. NOTT and MRC showed that survival benefit rises with more daily hours of use, with the greatest benefit at 17+ hours.<sup><a href=\"#ref-2\">2<\/a><\/sup><sup><a href=\"#ref-3\">3<\/a><\/sup> It is delivered via a stationary concentrator at home, with portable options for leaving the house. Most patients use a nasal cannula.<\/p>\n<h3>Ambulatory Oxygen Therapy<\/h3>\n<p>Ambulatory oxygen is supplemental oxygen used during physical activity or away from home. The evidence is mixed. Bradley and O&#8217;Neill&#8217;s 2005 Cochrane review found that short-term ambulatory oxygen can improve exercise endurance in laboratory settings, but longer-term real-world studies have not consistently shown improvements in daily function or quality of life.<sup><a href=\"#ref-6\">6<\/a><\/sup> It is typically delivered via portable concentrators or small compressed-gas cylinders. For device options, see our guide to <a href=\"https:\/\/regenerated.com\/blog\/portable-oxygen-therapy\/\">portable oxygen therapy<\/a>.<\/p>\n<h3>Nocturnal Oxygen Therapy<\/h3>\n<p>Some COPD patients hold acceptable oxygen levels during the day but desaturate during sleep. Nocturnal oxygen has not been shown to improve survival on its own, which NOTT demonstrated. It may still be appropriate when sleep-related desaturation is documented by overnight oximetry and is causing symptoms such as morning headaches or poor sleep.<\/p>\n<h2>When Does Oxygen Therapy NOT Help in COPD?<\/h2>\n<p>Oxygen is not a universal treatment for COPD symptoms, and this is where patients and even some clinicians get confused. The evidence is clear about its limits.<\/p>\n<ul>\n<li><strong>Moderate desaturation (SpO2 89 to 93%):<\/strong> the LOTT trial showed no benefit. Oxygen does not reduce hospitalizations, slow progression, or improve quality of life in this group.<sup><a href=\"#ref-4\">4<\/a><\/sup><\/li>\n<li><strong>Breathlessness without hypoxemia:<\/strong> feeling short of breath does not mean oxygen levels are low. Many COPD patients have dyspnea with normal SpO2, and supplemental oxygen does not reliably relieve it, per the 2020 American Thoracic Society guideline.<sup><a href=\"#ref-7\">7<\/a><\/sup><\/li>\n<li><strong>Isolated exercise desaturation (without severe resting hypoxemia):<\/strong> using oxygen only during exercise, when resting levels are normal, has not been shown to improve long-term outcomes.<\/li>\n<\/ul>\n<h2>What Do the GOLD 2024 Guidelines Recommend?<\/h2>\n<p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 report gives the most current evidence-based recommendations:<sup><a href=\"#ref-1\">1<\/a><\/sup><\/p>\n<ul>\n<li>LTOT is recommended for patients with severe resting hypoxemia (PaO2 at or below 55 mmHg or SpO2 at or below 88%).<\/li>\n<li>LTOT should be used for a minimum of 15 hours daily.<\/li>\n<li>Target SpO2 should be 88 to 92% during both stable state and acute exacerbations.<\/li>\n<li>LTOT is NOT recommended for patients with moderate desaturation, based on LOTT.<\/li>\n<li>Oxygen during acute exacerbations should be titrated carefully, never exceeding 28% FiO2 initially, to avoid worsening hypercapnia.<\/li>\n<li>All patients on LTOT should be reassessed after 60 to 90 days to confirm ongoing need.<\/li>\n<\/ul>\n<h2>What Are the Risks and Side Effects?<\/h2>\n<p>Oxygen is a drug, and like any drug it carries risks, especially in COPD. Our guides to <a href=\"https:\/\/regenerated.com\/blog\/oxygen-therapy-safety-precautions\/\">oxygen therapy safety precautions<\/a> and <a href=\"https:\/\/regenerated.com\/blog\/oxygen-therapy\/\">oxygen therapy contraindications<\/a> cover these in depth.<\/p>\n<ul>\n<li><strong>Oxygen-induced hypercapnia:<\/strong> over-oxygenation can suppress respiratory drive in CO2-retaining patients, causing dangerous CO2 buildup. This is the most serious risk and the reason for the 88 to 92% target.<\/li>\n<li><strong>Nasal dryness and irritation:<\/strong> continuous cannula use dries the nasal passages; a humidifier bottle on the oxygen source helps.<\/li>\n<li><strong>Fire hazard:<\/strong> oxygen supports combustion, so patients must avoid open flames, smoking, and some aerosol products while using it.<\/li>\n<li><strong>Restricted mobility:<\/strong> stationary concentrators limit movement; portable units help but add weight and need charging or refilling.<\/li>\n<li><strong>Oxygen toxicity:<\/strong> prolonged high concentrations can damage lung tissue, though this is mainly a concern above 60% FiO2 for extended periods, which is not typical of home LTOT.<\/li>\n<\/ul>\n<p>Acute respiratory failure in COPD sometimes overlaps with conditions like ARDS, where oxygen and ventilation strategy differ. See our guide to <a href=\"https:\/\/regenerated.com\/blog\/oxygen-therapy\/\">oxygen therapy for ARDS<\/a> for that distinction.<\/p>\n<h2>What Is Living With Oxygen Therapy Like?<\/h2>\n<p>For patients who qualify for LTOT, compliance matters directly. The survival benefit in NOTT tracked daily hours of use, and patients who used oxygen 17+ hours daily had the best outcomes.<sup><a href=\"#ref-2\">2<\/a><\/sup><\/p>\n<ul>\n<li>Use oxygen during sleep, when desaturation tends to be worst.<\/li>\n<li>Carry a portable unit when leaving the house.<\/li>\n<li>Keep backup supplies in case of equipment failure.<\/li>\n<li>Notify your electricity provider that you use life-sustaining equipment at home.<\/li>\n<li>Keep a written action plan for acute exacerbations.<\/li>\n<li>Get regular follow-up to confirm your flow rate is still appropriate.<\/li>\n<\/ul>\n<p>Hyperbaric oxygen therapy (HBOT) is a different modality that delivers oxygen at pressures above atmospheric levels and serves a different clinical purpose than standard supplemental oxygen. You can read more about <a href=\"https:\/\/regenerated.com\/blog\/hyperbaric-chamber-for-copd\/\">HBOT for COPD here<\/a>.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"bb-faq\">\n<div class=\"bb-faq-item\">\n<h3>Can you use too much oxygen with COPD?<\/h3>\n<div class=\"bb-faq-answer\">\n<p>Yes. Pushing SpO2 above 92% can suppress the breathing drive in COPD patients who retain CO2, leading to worsening hypercapnia, respiratory acidosis, and in severe cases respiratory failure. Austin and colleagues (BMJ, 2010) found that high-flow oxygen targeting 100% saturation raised mortality versus titrated oxygen targeting 88 to 92%. That is why the target range is 88 to 92%, not 95%+.<\/p>\n<\/div>\n<\/div>\n<div class=\"bb-faq-item\">\n<h3>Does oxygen therapy cure COPD?<\/h3>\n<div class=\"bb-faq-answer\">\n<p>No. Oxygen therapy treats hypoxemia, a consequence of COPD. It does not reverse lung damage, slow the decline in lung function, or cure the underlying disease. Its proven benefit, established by the NOTT and MRC trials, is reducing mortality in patients with severe resting hypoxemia who use it at least 15 hours a day.<\/p>\n<\/div>\n<\/div>\n<div class=\"bb-faq-item\">\n<h3>How many hours per day should a COPD patient use oxygen?<\/h3>\n<div class=\"bb-faq-answer\">\n<p>For LTOT to provide survival benefit, a minimum of 15 hours per day is required, per GOLD 2024. The NOTT trial showed that 17+ hours daily gave the greatest benefit, so the general recommendation is to use oxygen as close to continuously as possible, including during sleep.<\/p>\n<\/div>\n<\/div>\n<div class=\"bb-faq-item\">\n<h3>Is oxygen therapy the same as hyperbaric oxygen?<\/h3>\n<div class=\"bb-faq-answer\">\n<p>No. Standard oxygen therapy delivers supplemental oxygen at normal atmospheric pressure (1 ATA) through a nasal cannula or mask. Hyperbaric oxygen therapy delivers 100% oxygen at 1.5 to 3.0 ATA inside a sealed chamber. They are different treatments with different indications.<\/p>\n<\/div>\n<\/div>\n<div class=\"bb-faq-item\">\n<h3>Can I fly while on oxygen therapy?<\/h3>\n<div class=\"bb-faq-answer\">\n<p>Air travel is possible but requires planning. Cabin pressure at cruising altitude is lower than at sea level, which can worsen hypoxemia. Most COPD patients on LTOT need supplemental oxygen during flights. Airlines require advance notice and have specific policies about approved portable oxygen equipment on board.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"bb-references\">\n<h2>Sources<\/h2>\n<ol>\n<li id=\"ref-1\">Global Initiative for Chronic Obstructive Lung Disease (GOLD). &#8220;Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report.&#8221; <a href=\"https:\/\/goldcopd.org\/2024-gold-report\/\" target=\"_blank\" rel=\"noopener\">goldcopd.org<\/a><\/li>\n<li id=\"ref-2\">Nocturnal Oxygen Therapy Trial Group. &#8220;Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial.&#8221; <em>Annals of Internal Medicine<\/em>, 1980;93(3):391-398. <a href=\"https:\/\/doi.org\/10.7326\/0003-4819-93-3-391\" target=\"_blank\" rel=\"noopener\">doi:10.7326\/0003-4819-93-3-391<\/a><\/li>\n<li id=\"ref-3\">Medical Research Council Working Party. &#8220;Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema.&#8221; <em>The Lancet<\/em>, 1981;1(8222):681-686. PMID: 6110912.<\/li>\n<li id=\"ref-4\">Long-Term Oxygen Treatment Trial Research Group. &#8220;A randomized trial of long-term oxygen for COPD with moderate desaturation.&#8221; <em>New England Journal of Medicine<\/em>, 2016;375(17):1617-1627. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1604344\" target=\"_blank\" rel=\"noopener\">doi:10.1056\/NEJMoa1604344<\/a><\/li>\n<li id=\"ref-5\">Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. &#8220;Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial.&#8221; <em>BMJ<\/em>, 2010;341:c5462. <a href=\"https:\/\/doi.org\/10.1136\/bmj.c5462\" target=\"_blank\" rel=\"noopener\">doi:10.1136\/bmj.c5462<\/a><\/li>\n<li id=\"ref-6\">Bradley JM, O&#8217;Neill B. &#8220;Short-term ambulatory oxygen for chronic obstructive pulmonary disease.&#8221; <em>Cochrane Database of Systematic Reviews<\/em>, 2005;(4):CD004356. <a href=\"https:\/\/doi.org\/10.1002\/14651858.CD004356.pub3\" target=\"_blank\" rel=\"noopener\">doi:10.1002\/14651858.CD004356.pub3<\/a><\/li>\n<li id=\"ref-7\">Jacobs SS, Krishnan JA, Engel PJ, et al. &#8220;Home oxygen therapy for adults with chronic lung disease: an official American Thoracic Society clinical practice guideline.&#8221; <em>American Journal of Respiratory and Critical Care Medicine<\/em>, 2020;202(10):e121-e141. <a href=\"https:\/\/doi.org\/10.1164\/rccm.202009-3608ST\" target=\"_blank\" rel=\"noopener\">doi:10.1164\/rccm.202009-3608ST<\/a><\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Long-term oxygen therapy is the single treatment proven to extend life in COPD patients with severe hypoxemia. Two&hellip;<\/p>\n","protected":false},"author":1,"featured_media":7490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[998],"tags":[],"class_list":["post-7491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oxygen-energy-therapies"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/7491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=7491"}],"version-history":[{"count":1,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/7491\/revisions"}],"predecessor-version":[{"id":7492,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/7491\/revisions\/7492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media\/7490"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=7491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=7491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=7491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}